Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine

por Rendas-Baum, Regina, Yang, Min, Varon, Sepideh F, Bloudek, Lisa M, DeGryse, Ronald E, Kosinski, Mark
Publicado 2014

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program

por Lipton, Richard B, Rosen, Noah L, Ailani, Jessica, DeGryse, Ronald E, Gillard, Patrick J, Varon, Sepideh F
Publicado 2016

Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis

por Diener, Hans-Christoph, Dodick, David W., Lipton, Richard B., Manack Adams, Aubrey, DeGryse, Ronald E., Silberstein, Stephen D.
Publicado 2020

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine

por Silberstein, Stephen D., Diener, Hans-Christoph, Dodick, David W., Manack Adams, Aubrey, DeGryse, Ronald E., Lipton, Richard B.
Publicado 2020

Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT

por Silberstein, Stephen D, Dodick, David W, Aurora, Sheena K, Diener, Hans-Christoph, DeGryse, Ronald E, Lipton, Richard B, Turkel, Catherine C
Publicado 2015